[6-K] Intercure Ltd. Current Report (Foreign Issuer)
Rhea-AI Filing Summary
InterCure Ltd. reported that it will hold its Annual General Meeting of Shareholders on December 30, 2025 at 4:00 p.m. (Israel time) at the offices of its legal counsel in Tel Aviv, Israel. The company is providing shareholders with a Notice and Proxy Statement describing the proposals to be voted on and the procedures for voting in person or by proxy, together with a Proxy Card that enables holders of ordinary shares to vote without attending the meeting. These materials are furnished as exhibits to the report so shareholders can review the agenda and participate in the decision-making process for the company.
Positive
- None.
Negative
- None.
FAQ
What did InterCure Ltd. (INCR) announce in this Form 6-K?
InterCure Ltd. announced that it will hold its Annual General Meeting of Shareholders and is furnishing a Notice and Proxy Statement and a Proxy Card related to that meeting.
When and where is InterCure Ltd.'s 2025 Annual General Meeting of Shareholders?
The meeting is scheduled for December 30, 2025 at 4:00 p.m. (Israel time) at the offices of Amit, Pollak, Matalon & Co., APM House, 18 Raoul Wallenberg St., Building D, 6th floor, Ramat Hachayal, Tel Aviv, Israel.
What documents did InterCure Ltd. provide in connection with the Annual General Meeting?
The company furnished a Notice and Proxy Statement as Exhibit 99.1 and a Proxy Card for holders of ordinary shares as Exhibit 99.2.
How can InterCure (INCR) shareholders vote if they do not attend the meeting in person?
Holders of ordinary shares may vote without attending in person by using the Proxy Card provided as Exhibit 99.2, following the procedures described in the Notice and Proxy Statement.
What information is contained in InterCure Ltd.'s Notice and Proxy Statement?
The Notice and Proxy Statement describe the proposals to be voted upon at the meeting, the procedure for voting in person or by proxy, and other details related to the Annual General Meeting.
Who signed the Form 6-K on behalf of InterCure Ltd.?
The report was signed on behalf of InterCure Ltd. by Amos Cohen, Chief Financial Officer.